Multivariate analyses for the impact of individual H-Y antigen IgGs on clinical outcomes
| . | Serostatus . | n . | HR* (95% CI) . | P . |
|---|---|---|---|---|
| cGVHD | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 3.03 (1.58-5.8) | .0009 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 2.39 (1.48-3.88) | .0004 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 1.55 (0.84-2.85) | .16 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 1.99 (1.24-3.17) | .004 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 2.43 (1.39-4.25) | .0018 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 3.62 (1.81-7.22) | .0003 | |
| NRM | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 7.28 (1.93-27.5) | .0034 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 4.90 (1.61-15.0) | .0053 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 3.42 (1.15-10.1) | .027 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 5.78 (1.30-25.7) | .021 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 6.93 (1.81-26.5) | .0047 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 6.00 (1.34-27.0) | .019 | |
| Relapse | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 0.50 (0.16-1.54) | .23 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 0.65 (0.26-1.62) | .35 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 0.52 (0.17-1.60) | .25 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 0.79 (0.40-1.56) | .5 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 0.47 (0.21-1.02) | .06 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 0.53 (0.16-1.71) | .29 | |
| OS | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 1.97 (0.96-4.03) | .064 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 1.10 (0.52-2.31) | .8 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 1.40 (0.67-2.93) | .37 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 1.63 (0.87-3.05) | .13 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 0.92 (0.49-1.75) | .8 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 1.60 (0.76-3.35) | .22 |
| . | Serostatus . | n . | HR* (95% CI) . | P . |
|---|---|---|---|---|
| cGVHD | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 3.03 (1.58-5.8) | .0009 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 2.39 (1.48-3.88) | .0004 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 1.55 (0.84-2.85) | .16 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 1.99 (1.24-3.17) | .004 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 2.43 (1.39-4.25) | .0018 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 3.62 (1.81-7.22) | .0003 | |
| NRM | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 7.28 (1.93-27.5) | .0034 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 4.90 (1.61-15.0) | .0053 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 3.42 (1.15-10.1) | .027 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 5.78 (1.30-25.7) | .021 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 6.93 (1.81-26.5) | .0047 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 6.00 (1.34-27.0) | .019 | |
| Relapse | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 0.50 (0.16-1.54) | .23 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 0.65 (0.26-1.62) | .35 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 0.52 (0.17-1.60) | .25 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 0.79 (0.40-1.56) | .5 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 0.47 (0.21-1.02) | .06 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 0.53 (0.16-1.71) | .29 | |
| OS | ||||
| DBY | Negative | 110 | 1 | |
| Positive | 26 | 1.97 (0.96-4.03) | .064 | |
| EIF1AY | Negative | 109 | 1 | |
| Positive | 27 | 1.10 (0.52-2.31) | .8 | |
| RPS4Y | Negative | 111 | 1 | |
| Positive | 25 | 1.40 (0.67-2.93) | .37 | |
| SMCY | Negative | 86 | 1 | |
| Positive | 50 | 1.63 (0.87-3.05) | .13 | |
| UTY | Negative | 91 | 1 | |
| Positive | 45 | 0.92 (0.49-1.75) | .8 | |
| ZFY | Negative | 115 | 1 | |
| Positive | 21 | 1.60 (0.76-3.35) | .22 |
HR, hazard ratio.
HRs of seropositivity of individual H-Y antigen IgGs are shown after adjusting for age of patient and donor, disease, disease risk, CMV serostatus, donor types, cell sources, usage of total body irradiation, usage of anti-thymocyte globulin, and grade of aGVHD.